Glumetinib

谷美替尼

Report date: 2025/02/06 09:11:50
NME

Base Information

Drug NameGlumetinib
Drug Alias NameGumarontinib古马隆替尼海益坦HaiyitanHH-SCC244 +[7] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionHepatocyte growth factor receptor inhibitors
TargetsHepatocyte growth factor receptor
Therapy Area/IndicationsSolid tumoursCarcinoma, Non-Small-Cell Lung
Global Approved IndicationsCarcinoma, Non-Small-Cell Lung
Approved Indications in ChinaCarcinoma, Non-Small-Cell Lung
Original Approved Country/TerritoryMainland China
Original Approved Date2023/03/07
Country/TerritoryUnited StatesMainland ChinaJapan
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesShanghai Institute Of Materia Medica, Chinese Academy Of SciencesShangHai HaiHe Biopharma Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesTaiho Pharmaceutical Co LtdHaihe Biopharma (HK) LtdShanghai Greenvalley Pharmaceutical Co Ltd +[5] 
Inactive CompaniesShanghai Jmt-Bio IncHaimen Pharma IncShanghai Junshi Biosciences Co Ltd
Active IndicationsSolid tumoursCarcinoma, Non-Small-Cell Lung
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksDrugBank